Polymorphic N-acetylation capacity in lung cancer.
Hepatic N-acetylation phenotype has been suggested to be an important risk factor in the aetiology of bladder cancer. This study explores the N-acetylation capacity of a series of lung cancer cases (126) and two control groups. No overall association of slow or rapid acetylators exists between cancer patients and controls. There is also no difference in the distribution of acetylation phenotypes amongst the histological subtypes.